What a two-tier cell bank system is

A two-tier cell bank system exists so that the characterized starting material is never consumed by routine production. The master cell bank is made once, from a single clone, and tested in depth. Each working cell bank is expanded from one MCB vial, tested to a lighter panel, and used to seed production runs.

The system fixes three variables that otherwise drift. Passage number is capped, because every batch starts the same number of population doublings from the MCB. Genetic identity is anchored, because the MCB is the reference for end-of-production cells. Adventitious agent risk is contained, because exhaustive viral and mycoplasma testing is done once, on the MCB, and inherited by every WCB.

A research cell bank made in a development laboratory is not a substitute. It lacks the GMP documentation, the controlled environment and the test panel that regulators expect of a bank used to make clinical material.

Regulatory framework: ICH Q5D, ICH Q5A(R2), FDA and EMA expectations

Five documents define what cGMP guidelines expect of a cell bank, and they divide the work cleanly. ICH Q5D (1997) covers the cell substrate: its history, the bank system and the characterization of each tier. ICH Q5A(R2) (2023) covers viral safety for the MCB, the WCB and end-of-production cells. ICH Q5B (1995) covers the expression construct. EU GMP Annex 2 and 21 CFR Part 610 cover how banks are made, stored and controlled.

FDA and EMA both review cell banking documentation in Module 3, section 3.2.S.2.3, Control of Materials.

Characterization tests for the master cell bank

The MCB carries the heaviest test burden because every later bank inherits its results. Q5D groups the testing under identity, purity and stability, and Q5A(R2) supplies the viral section.

Two points decide the size of the viral panel. A line exposed to bovine serum or porcine trypsin during derivation needs the corresponding virus tests even if the final medium is chemically defined. Rodent lines such as CHO and NS0 carry endogenous retrovirus-like particles that must be quantified, because viral clearance is sized against that load.

Working cell bank and end-of-production cell bank: when and why

A working cell bank is made when production begins, and an end-of-production cell bank is made when the process is defined at scale. The WCB protects the MCB from depletion. The end-of-production cells prove that the line is stable to the limit of in vitro cell age.

WCB testing can be lighter because the WCB descends from a fully tested bank. Identity, sterility, mycoplasma and an in vitro adventitious virus assay are standard, and Q5A(R2) allows the in vitro assay to be run on end-of-production cells derived from that WCB.

End-of-production cells are harvested from a production or representative scale-down run carried to or beyond the proposed limit of in vitro cell age. They are tested for retrovirus, adventitious viruses and construct integrity, and compared with the MCB. The comparison defines the passage limit written into the batch record, and it is usually completed on engineering or PPQ runs so that the limit reflects commercial conditions.

cGMP storage: monitoring, alarms and off-site backup

Storage is where most cell banking failures happen, and cGMP guidelines treat the freezer as a validated system. Banks are held in the vapor phase of liquid nitrogen, below −130 °C, to avoid cross-contamination through liquid and to stay below the glass transition of the cryoprotectant.

• Continuous temperature recording and liquid nitrogen level monitoring, retained for the life of the bank.
• Alarms on temperature, nitrogen level and door opening, routed to staff who can respond at any hour.
• Inventory control: each vial has a unique identifier and location; withdrawals are recorded and counts reconciled on a schedule.
• Split storage: EU GMP Annex 2 recommends dividing stocks between separate locations so that one freezer failure cannot destroy the bank.

Off-site backup is the point sponsors most often overlook. Holding part of the MCB in a second qualified facility, under the same monitoring and documentation, is the only protection against a site-level event such as fire or prolonged power loss.

Timing cell bank testing against the IND

The IND needs a fully tested master cell bank, and the BLA needs the complete three-tier data set. Between those points, testing is phased against clinical milestones.

The sequence has one hard dependency: viral testing of the MCB takes weeks because in vitro and in vivo assays run for defined observation periods. Starting cell banking as soon as the clone is selected keeps it off the critical path to the IND.

What to ask a cGMP cell banking provider

A cell banking provider should be able to show the facility, the documents and the test results that make a bank acceptable to FDA, EMA and PMDA reviewers. These questions separate a GMP cell bank from a research freeze with a certificate attached.

1. Is the bank prepared in a classified cleanroom under a batch record, with environmental monitoring during the fill?
2. Which hosts has the facility banked under the same quality system?
3. Which tests are run in-house and which are outsourced?
4. How is the storage unit monitored and alarmed, and what is the documented response time?
5. Is off-site backup offered, in what facility, and under whose quality agreement?
6. How is traceability maintained from the research cell bank through the MCB, WCB and end-of-production cells?
7. Can the provider supply the 3.2.S.2.3 narrative and test summaries ready for the IND?

Questions 1, 4 and 5 are the ones to verify on site. Cell banking is simple to describe and hard to run well, and the difference shows in the alarm log.